Stand Up To Cancer - Where the Money Goes

Where the Money Goes

What We Do  >  Where the Money Goes

100% of donations received from the public support Stand Up To Cancer’s collaborative cancer research programs. Our unique research models are expertly designed to initiate collaboration, accelerate the pace of cancer research, and clear the way for high-impact breakthroughs.

Stand Up To Cancer breaks down the traditional barriers to collaboration by allowing scientists and researchers across institutions and disciplines to come together and work toward a shared goal: beating cancer. Our projects are large enough to allow scientists to work together on key questions, and our milestone-driven approach focuses efforts on delivering truly meaningful outcomes for patients.


SU2C creates interdisciplinary Dream Teams that connect top-tier scientists, clinicians, patient advocates, and other experts across institutions to expedite the discovery process for new cancer treatments.

What we learn about one cancer often has great application to others. That’s why research and clinical trials are vital to getting effective treatments to patients. More than 180 clinical trials have been funded by SU2C, and over $603 million has been pledged to the work of more than 1,600 scientists.

Clinical Trials
Planned, Started, or Completed
$0 MM+

“The best dollar spent on cancer research in this country.”

Phillip A. Sharp, PhD
SU2C Scientific Advisory Committee Chairperson, Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology


When new areas of research are identified that could have significant patient impact and potential for breakthrough, SU2C acts quickly to push proposals in these areas from concept to reality. SU2C’s research teams study many cancer types, with a focus on today’s most innovative areas of cancer therapy, such as immunotherapy and epigenetics.


Pancreatic Cancer (19%)Leukemia/Leukaemia (5%)Breast Cancer (14%)Melanoma (4%)Lung Cancer (12%)Ovarian Cancer (3%)Not-Site Specific Cancer (10%)Myeloma (3%)Pediatric (9%)Brain Tumor (2%)Colon and Rectal Cancer (7%)Endometrial (2%)Prostate Cancer (7%)*Other Cancers (3%)

*Other Cancers (3%)

Urinary TractSarcoma (soft-tissue)Genital System, MaleNon-Hodgkin's LymphomaAnal CancerCervical CancerGastrointestinalKidneyGenital System, FemaleLiverLaryngealPharyngeal

Progress against one cancer is progress against all cancers. See what SU2C scientists are working on now.



SU2C’s network of scientists are laser-focused on research developments that can be moved quickly from the lab to the clinic. This approach, called translational research, brings new treatments to patients who need them now by closely involving clinical trial teams.

Learn how SU2C research models leverage collaboration, strategic risk-taking, and translational research to produce better results, faster.



The annual SU2C Summit unites SU2C-funded researchers from multiple areas of study to allow the SU2C model of collaboration to realize its full potential. Top scientists share findings, ideas, and progress reports, thereby fostering greater discovery, increasing transparency, promoting additional collaboration across teams and research programs, and encouraging thinking outside the traditional research silos.

“We bring in diverse expertise, anyone who can help with the cancer problem, including mathematicians, astrophysicists, computer scientists and the like. And that adds an incredible dimension.”

William G. Nelson, MD, PhD
SU2C Scientific Advisory Committee Vice Chair, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins


Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Thank you for your form submission. You will hear from us soon

Stand Up With Us Today

Cancer tragically connects all of us: our children, our siblings, our spouses, our friends and family. But in that connection, we can come together in triumph and Stand Up To Cancer.

Will you join us?

   Please leave this field empty

Thanks for signing up!

You'll hear from us soon.